PDE5A and diabetes mellitus: A significant reduction in the relaxant efficacy of the PDE5 inhibitor sildenafil was observed in the CC and PRAs of diabetic patients with ED with respect to those of ED patients without diabetes (Supplementary Figure S5A,B).